No material corporate news briefings were recorded for Amgen Inc. in the 30 days preceding this report's generation date of 2026-07-03. Prior reports dated 2026-06-25, 2026-06-17, and 2026-06-09 similarly noted the absence of material corporate news events within their respective windows [Brief - 2026-06-25] [Brief - 2026-06-17] [Brief - 2026-06-09]. This report is principally driven by notable institutional position changes recorded in recent 13F filings, supplemented by the most recent quarterly financial data available.
For the trailing twelve months ending 2026-03-31, Amgen reported revenue of $37.22 billion, representing year-over-year growth of 5.76%. Net income over the same period was $7.80 billion, yielding a net margin of 20.96%. Gross margin stood at 48.58% and operating margin at 28.39%. Earnings per share grew 4.38% year-over-year. The company held $12.04 billion in cash against total debt of $59.32 billion. Market capitalisation was recorded at approximately $201.93 billion, with a price-to-earnings ratio of 26.04 [SEC 10-Q - AMGN - 2026-03-31].
Institutional ownership activity showed notable divergence in the most recent 13F reporting period. Bridgewater added 389% to its AMGN position, representing the most substantial directional change among reported filers [SEC 13F - Bridgewater - Q1 2026]. Millennium Management added 47% to its position [SEC 13F - Millennium - Q1 2026]. Conversely, AQR Capital reduced its position by 30% [SEC 13F - AQR Capital - Q1 2026], and Citadel reduced its position by 9.4% [SEC 13F - Citadel - Q1 2026]. No insider transaction data was provided for the current reporting period.
The prevailing macroeconomic rate environment recorded the 10-year US Treasury yield at 4.48% and the 2-year yield at 4.17%, producing a normal yield curve with a spread of 31 basis points [FRED DGS10] [FRED DGS2]. This report was generated in response to material institutional position changes identified in the most recent round of 13F disclosures.